Programme
Please enter your password to join the recordings.
Day 1 | Friday, 24th May 2024

from 09:30
Registration

10:45
Welcome
Scientific committee

11:00-1:00
Session 1
The germinal center reaction as
a catalyst for lymphoma development

Chair

Christian Reinhardt
University Hospital Essen (GER)

11:00

Role of Super-enhancer
Hypermutation in the
Pathogenesis of Diffuse
Large B cell Lymphoma
Riccardo Dalla-Favera,
Columbia University New York (USA)

11:25

Genetics-driven epigenetic disruption
of the germinal center program
in B cell lymphomas
Laura Pasqualucci,
Columbia University New York (USA)

11:50

Aspects of Hodgkin lymphoma biology
Ralf Küppers,
University Hospital Essen (GER)

12:15

Modelling Sporadic Oncogenic Events
in Lympho magenesis
Dinis Calado,
The Francis Crick Institute London (UK)

12:50
Discussion
1:00-2:00
Break


2:00-4:00
Session 2
Epigenetic rewiring as a driver
and target of lymphomagenesis

Chair

Peter Borchmann
University Hospital Cologne (GER)

2:00

Mechanisms and therapeutic targeting
of the malignant immune system
Ari M. Melnick,
Weill Cornell Medicine New York (USA)

2:25

Development of small molecules
for epigenetic targets
Othman Al-Sawaf,
Universitätsklinikum Köln (GER)

2:50

Harnessing state switches
in aggressive B-cell lymphoma
Clemens Schmitt,
Charité – University Hospital Berlin (GER)

3:15

DNA-methylation based classification
of lymphomas: A tool to come?
Reiner Siebert,
Ulm University Hospital (GER)

3:40

Remote contribution
Toward the noninvasive characterization
of lymphomas & their microenvironments
Ash A. Alizadeh,
Stanford University / Stanford
Comprehensive Cancer Center (USA)

4:00-6:00
Poster presentation and
Get together
Day 2 | Saturday, 25th May 2024

8:00-10:00
Session 3
Genetic rewiring encodes actionable
vulnerabilities in lymphoma

Chair

Sascha Dietrich
University Hospital Düsseldorf (GER)

8:00

Genetic bases of immune evasion in lymphoma
Margaret Shipp,
Dana Farber/Harvard Cancer Center
Boston (USA)

8:25

Curing aggressive lymphomas
with aggressive combinations
of targeted agents
Louis Staudt,
National Cancer Institute Bethesda (USA)

8:50

Actionable Alterations in LBCL
Björn Chapuy,
Charité University Medicine Berlin (GER)

9:15

Elucidation of Lymphoma Proteogenotypes
Thomas Oellerich,
University Hospital Frankfurt (GER)

9:50
Discussion
10:00-10:30
Break


10:30-12:00
Session 2
Epigenetic rewiring as a driver
and target of lymphomagenesis

Chair

Peter Borchmann
University Hospital Cologne (GER)

02:00

Ari M. Melnick
Weill Cornell Medicine New York (USA)

02:25

Stefan Knapp
Goethe-University Frankfurt (GER)

02:50

Clemens Schmitt
Charité – University Hospital Berlin (GER)

03:15

Rainer Siebert
Ulm University Hospital (GER)

09:40
Short talk II

09:50
Discussion

10:30-12:30
Session 4
The next frontier: harnessing the
immune system for lymphoma therapy

Chair

Bastian von Tresckow
University Hospital Essen (GER)

10:30

Chemotherapy free approaches
in first line LBCL – a dream or a reality?
Jason Westin,
University of Texas MD Anderson Cancer
Center Houston (USA)

10:55

Enhancing immunotherapies for germinal
center-derived B cell lymphomas by
EZH2 inhibition
Wendy Béguelin,
Weill Cornell Medicine New York, (USA)

11:20

Multi-omic profiling of CAR T cell
treated aggressive B-cell
lymphoma reveals a CSF1R+
myeloid-monocytic cell
compartment mediating
CAR T cell resistance
Roland Ullrich,
University Hospital Cologne (GER)

11:45

Bispecific T Cell Engagers
in Follicular Lymphoma:
Promises and Path Ahead
Elisabeth Budde,
City of Hope National MedicalCenter Duarte (USA)

12:10

Multimodal and spatially resolved profiling
identifies distinct patterns of T cell infiltration
in nodal B cell lymphoma entities
Sascha Dietrich,
University Hospital Düsseldorf (GER)

12:35
Discussion
12:45-1:45
Break


1:45-3:30
Session 5
Mechanisms of resistance and
definition of high-risk DLBCL

Chair

Ralf Küppers
University Hospital Essen (GER)

1:55

Mechanisms of resistance and
definition of high-risk DLBCL
Andrew Davies,
Southampton General Hospital (UK)

2:20

Overcoming therapy resistance
through single-cell functional precision
medicine approaches
Philipp Staber,
Medical University of Vienna (AUT)

2:45

Autochthonous mouse models of DLBCL
enable in vivo genetic screening and
serve as a platorm for preclinical validation
of actionable vulnerabilities
Christian Reinhardt,
University Hospital Essen (GER)

3:10
Discussion

3:30
Closing remarks
Farewell and Goodbye
Status 05/2024, subject to change.